Danske Bank A S Acquires Shares of 3,190,647 Pfizer Inc. $PFE

Danske Bank A S bought a new position in Pfizer Inc. (NYSE:PFE) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 3,190,647 shares of the biopharmaceutical company’s stock, valued at approximately $81,298,000. Danske Bank A S owned about 0.06% of Pfizer as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of PFE. Brighton Jones LLC grew its position in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC raised its position in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares in the last quarter. United Bank lifted its stake in Pfizer by 12.4% during the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after purchasing an additional 6,415 shares during the last quarter. Avantax Advisory Services Inc. lifted its stake in Pfizer by 14.6% during the second quarter. Avantax Advisory Services Inc. now owns 423,497 shares of the biopharmaceutical company’s stock worth $10,266,000 after purchasing an additional 54,086 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. lifted its stake in Pfizer by 8.8% during the second quarter. Nomura Asset Management Co. Ltd. now owns 2,112,648 shares of the biopharmaceutical company’s stock worth $51,211,000 after purchasing an additional 171,223 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported positive topline Phase 2 results for its next‑generation CDK4 inhibitor atirmociclib in HR+/HER2‑ metastatic breast cancer — the combo reduced risk of progression or death by ~40% versus control, positioning atirmociclib as a potential successor to Ibrance and a meaningful oncology revenue driver if confirmed in later trials. Pfizer Announces Positive Topline Phase 2 Results for Atirmociclib
• Positive Sentiment: Major media and wire outlets (Reuters/BusinessWire) highlighted the trial win and its magnitude (40% risk reduction), which is driving optimism around Pfizer’s oncology strategy and helps the stock’s re‑rating story. Reuters: Pfizer experimental breast cancer drug cuts risk
• Positive Sentiment: HSBC raised its price target to $32 and maintained a Buy rating, giving institutional support and signaling ~16% upside to analysts’ consensus targets — a catalyst for near‑term buying. Benzinga: HSBC raises Pfizer PT
• Positive Sentiment: Competitive dynamics improved after a rival (Bicycle) scaled back a Padcev challenger, reducing near‑term competitive pressure on Pfizer’s fast‑selling bladder cancer drug. That lowers some downside risk to future sales. BioPharmaDive: Bicycle layoffs, Padcev challenger deprioritized
• Neutral Sentiment: Jim Cramer and other commentators noted Pfizer’s sizable pipeline (retail interest), which can boost retail flows but doesn’t change fundamentals absent confirmatory Phase 3 data or regulatory actions. Yahoo: Jim Cramer on Pfizer pipeline
• Neutral Sentiment: Coverage and attention pieces (Zacks, IP Group mentions) point to rising investor focus and deal flow benefits (e.g., prior Metsera deal), but these are incremental until monetized or reflected in guidance. Zacks: Pfizer attracting attention
• Negative Sentiment: Longer‑term risk reminder: analysts and commentators caution that Pfizer still faces revenue pressure from loss of COVID exclusivity and other patent cliffs — positive trial news helps re‑rate but does not eliminate those macro risks. The Motley Fool: Key risks for Pfizer

Pfizer Stock Up 3.2%

Pfizer stock opened at $27.47 on Wednesday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94. The company has a 50-day simple moving average of $26.57 and a 200-day simple moving average of $25.56. The firm has a market capitalization of $156.21 billion, a P/E ratio of 20.20 and a beta of 0.47.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. Pfizer’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same period last year, the firm posted $0.63 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on PFE. Daiwa Securities Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price for the company. in a research note on Thursday, February 12th. Barclays assumed coverage on shares of Pfizer in a research report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price target on the stock. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the company an “underperform” rating in a report on Wednesday, December 17th. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective on the stock in a research note on Monday, March 2nd. Finally, Citigroup initiated coverage on Pfizer in a research note on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $28.14.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.